Cargando…

Patient and parent preferences for characteristics of prophylactic treatment in hemophilia

INTRODUCTION: New longer-acting factor products will potentially allow for less frequent infusion in prophylactic treatment of hemophilia. However, the role of administration frequency relative to other treatment attributes in determining preferences for prophylactic hemophilia treatment regimens is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Furlan, Roberto, Krishnan, Sangeeta, Vietri, Jeffrey
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4664548/ https://www.ncbi.nlm.nih.gov/pubmed/26648701 http://dx.doi.org/10.2147/PPA.S92520

Ejemplares similares

Aspects of prophylactic treatment of hemophilia
por: Ljung, Rolf
Publicado: (2016)

Understanding patient preferences and willingness to pay for hemophilia therapies
por: Chaugule, Shraddha S, et al.
Publicado: (2015)

Patient preferences in the treatment of hemophilia A: impact of storage conditions on product choice
por: Tischer, Bernd, et al.
Publicado: (2018)

Indirect Treatment Comparison of Damoctocog Alfa Pegol versus Turoctocog Alfa Pegol as Prophylactic Treatment in Patients with Hemophilia A
por: Vashi, Parth, et al.
Publicado: (2021)

Model-Informed Support of Dose Selection for Prophylactic Treatment with Dalcinonacog Alfa in Adult and Paediatric Hemophilia B Patients
por: Faraj, Alan, et al.
Publicado: (2023)

The frequency of complications in a cohort of patients diagnosed with hemophilia A and hemophilia B receiving prophylactic treatment in Colombia: A retrospective noninterventional study
por: Machado Alba, Jorge E., et al.
Publicado: (2023)

Patient preferences in the treatment of hemophilia A: A latent class analysis
por: Mühlbacher, Axel C., et al.
Publicado: (2021)

Prophylactic emicizumab for hemophilia A in the Asia‐Pacific region: A randomized study (HAVEN 5)
por: Yang, Renchi, et al.
Publicado: (2022)

Validation of the Brazilian version of the VERITAS-Pro scale to assess adherence to prophylactic regimens in hemophilia
por: Ferreira, Adriana Aparecida, et al.
Publicado: (2018)

Effectiveness of Prophylactic Coagulation Factor Replacement Therapy in Patients with Severe Hemophilia A in Taiwan – A Population-Based Study
por: Hsieh, Miyuki Hsing-Chun, et al.
Publicado: (2022)

Concizumab as a Subcutaneous Prophylactic Treatment Option for Patients with Hemophilia A or B: A Review of the Evidence and Patient’s Perspectives
por: Pasca, Samantha
Publicado: (2022)

Quantifying Benefit-Risk Trade-Offs Toward Prophylactic Treatment Among Adult Patients With Hemophilia A in China: Discrete Choice Experiment Study
por: Wang, Limin, et al.
Publicado: (2023)

Matching-adjusted indirect comparisons of efficacy of BAY 81-8973 vs two recombinant factor VIII for the prophylactic treatment of severe hemophilia A
por: Pocoski, Jennifer, et al.
Publicado: (2016)

Once-weekly prophylactic dosing of recombinant factor IX improves adherence in hemophilia B
por: Djambas Khayat, Claudia
Publicado: (2016)

Gene Therapy for Hemophilia A: A Mixed Methods Study of Patient Preferences and Shared Decision-Making
por: Limjoco, Jacqueline, et al.
Publicado: (2023)

Preferences and Health-Related Quality-of-Life Related to Disease and Treatment Features for Patients with Hemophilia A in a Canadian General Population Sample
por: Johnston, Karissa, et al.
Publicado: (2021)

Preferences for Adult Pneumococcal Vaccine Recommendations Among United States Health Care Providers
por: Sacco, Patricia, et al.
Publicado: (2019)

Treatment of Hemophilia
Publicado: (1896)

Costs and utilization of treatment in patients with hemophilia
por: Rocha, Patrícia, et al.
Publicado: (2015)

Comparison of extended to standard half-life recombinant factor VIII therapy in patients with hemophilia A on prophylactic therapy
por: McCall, Michael, et al.
Publicado: (2019)

Treatment for Osteoporosis among Women in Japan: Associations with Patient Characteristics and Patient-Reported Outcomes in the 2008–2011 Japan National Health and Wellness Surveys
por: Sato, Masayo, et al.
Publicado: (2014)

Manual therapy in the treatment of patients with hemophilia B and inhibitor
por: Cuesta-Barriuso, Rubén, et al.
Publicado: (2018)

Correlations between patient-reported outcomes and self-reported characteristics in adults with hemophilia B and caregivers of children with hemophilia B: analysis of the B-HERO-S study
por: Buckner, Tyler W, et al.
Publicado: (2019)

Health care utilization and expenditures of parents of children with and without hemophilia A
por: Kim, Eunice, et al.
Publicado: (2022)

Therapeutic and routine prophylactic properties of rFactor VIII Fc (efraloctocog alfa, Eloctate(®)) in hemophilia A
por: Chowdary, Pratima, et al.
Publicado: (2016)

Patient Preferences to Assess Value IN Gene Therapies: Protocol Development for the PAVING Study in Hemophilia
por: van Overbeeke, Eline, et al.
Publicado: (2021)

Understanding treatment burden in hemophilia: development and validation of the Hemophilia Treatment Experience Measure (Hemo-TEM)
por: Brod, Meryl, et al.
Publicado: (2023)

Treatment adherence in hemophilia
por: Thornburg, Courtney D, et al.
Publicado: (2017)

Pathogenesis and treatment of osteoporosis in patients with hemophilia
por: Lin, Xiaoyun, et al.
Publicado: (2023)

Practice of Iranian Adolescents with Hemophilia in Prevention of Complications of Hemophilia
por: Valizadeh, Leila, et al.
Publicado: (2015)

Clinical analysis of hospitalized patients with hemophilia A: single-hemophilia treatment center experience in Korea over 10 years
por: Kim, Ju Young, et al.
Publicado: (2021)

Bone fractures and feeling at risk for osteoporosis among women in Japan: patient characteristics and outcomes in the National Health and Wellness Survey
por: Sato, Masayo, et al.
Publicado: (2014)

Evaluation of Health-Related Values and Preferences of Adults Who Were Preterm Infants and Parents of Preterm Infants Concerning Use of Prophylactic Cyclooxygenase Inhibitor Drugs
por: Mitra, Souvik, et al.
Publicado: (2023)

Assessing prophylactic use and clinical outcomes in hemophilia A patients treated with rVIII‐SingleChain and other common rFVIII products in Germany
por: Olivieri, Martin, et al.
Publicado: (2020)

Patient Perceptions of and Preferences Between Characteristics of Injectable Diabetes Treatments
por: Boye, Kristina S., et al.
Publicado: (2021)

A survey of characteristics and current educational needs of hemophilia treatment centers within Asia Pacific
por: Lam, Joyce C. M., et al.
Publicado: (2018)

Characteristics of BAY 2599023 in the Current Treatment Landscape of Hemophilia A Gene Therapy
por: Pipe, Steven W., et al.
Publicado: (2023)

Capturing daily assessments and home treatment of congenital hemophilia with inhibitors: design, disposition, and implications of the Dosing Observational Study in Hemophilia (DOSE)
por: Young, Guy, et al.
Publicado: (2012)

Factors Influencing Parents' Preferences and Parents' Perceptions of Child Preferences of Picturebooks
por: Wagner, Laura
Publicado: (2017)

Seroprevalence and clinical characteristics of viral hepatitis in transfusion-dependent thalassemia and hemophilia patients
por: Jang, Tyng-Yuan, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_6usc0e2vrr0q8e9s552aaf9ut2